Colorectal cancer is the third leading cause of death due to cancer among women and men in the US. Each year, more than 140,000 Americans are diagnosed with colon cancer, and more than 50,000 die from it.
In addition to lifestyle influence, genetic risk factors are known to play a significant role in the development of colon cancer. While as many as 25% of cases are associated with a family history of the disease, 5% of cases develop in the setting of an established familial genetic syndrome. Those with a family history of colorectal cancer in two or more first-degree relatives have a two to three folds greater risk of disease. A number of genetic syndromes are also associated with higher rates of colorectal cancer.
Colorectal Cancer Risk Gene Testing (Gx™ CoReCa)
Gx™ Colorectal Cancer Gene Panel analyzes 20 genes known to be associated with an increased risk of colorectal cancer.
Colorectal Cancer Genes – 20 genes
APC, ATM, BMPR1A, BRCA1, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH3, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
Gx™ CoReCa testing helps to identify gene variants associated with colorectal cancer, assesses colorectal cancer risk, and facilitates diagnosis of cancers.
Alternative options to test for related Lynch Syndrom Gene Testing (Gx™ LynS) or a more comprehensive Inherited Cancer Risk Assessment Gene Testing (Gx™ InhCa) are available.
Test Name: Gx™ Colorectal Cancer Gene Testing
Test ID: Gx™ CoReCa
Turn-Around Time: 2-3 weeks for Clinical Testing and Report
Specimen Requirement: Saliva, iSWAB, SWAB in preservation solutions, Whole Blood/LavTop or gDNA, or inquire
Colorectal Cancer Booklet, Physician Booklet Expanded
Colorectal Cancer Booklet, Physician Booklet